SELDI-TOF-MS proteomics of breast cancer

被引：51

作者：

Clarke, CH

Buckley, JA

Fung, ET

机构：

[1] Ciphergen Biosyst Inc, Div Diagnost, Fremont, CA 94555 USA

[2] Palo Alto Med Fdn, Dept Radiol, Palo Alto, CA USA

来源：

CLINICAL CHEMISTRY AND LABORATORY MEDICINE | 2005年 / 43卷 / 12期

关键词：

biomarkers; breast cancer; diagnostics; proteomics; surface enhanced laser desorption/ionization (SELDI);

D O I：

10.1515/CCLM.2005.225

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

The detection, diagnosis, and management of breast cancer rely on an integrated approach using clinical history, physical examination, imaging, and histopathology. The discovery and validation of novel biomarkers will aid the physician in more effectively achieving this integration. This review discusses efforts in surface-enhanced laser desorption/ionization (SELDI)-based proteomics to address various clinical questions surrounding breast cancer, including diagnosis, monitoring, and stratification for treatment. Emphasis is placed on examining how study design and execution influence the discovery and validation process, which is critical to the proper development of potential clinical tests.

引用

页码：1314 / 1320

页数：7

共 55 条

[21]

Hu Yue, 2005, Ai Zheng, V24, P67

[22] The SELDI-TOF MS approach to proteomics: Protein profiling and biomarker identification [J].